Cargando…

Tumor invasion in the central airway is a risk factor for early‐onset checkpoint inhibitor pneumonitis in patients with non‐small cell lung cancer

BACKGROUND: Anti‐programmed death‐1 (PD‐1) immunotherapy can cause immune‐related pneumonitis, also known as checkpoint inhibitor pneumonitis (CIP). CIP that develops early after the initiation of anti‐PD‐1 immunotherapy is important because it is more severe than CIP that develops later. However, o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moda, Mitsuhiro, Saito, Haruhiro, Kato, Terufumi, Usui, Ryo, Kondo, Tetsuro, Nakahara, Yoshiro, Murakami, Shuji, Yamamoto, Kouji, Yamada, Kouzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705619/ https://www.ncbi.nlm.nih.gov/pubmed/33078531 http://dx.doi.org/10.1111/1759-7714.13703

Ejemplares similares

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing
por: Murakami, Shuji, et al.
Publicado: (2021)

Radiation recall pneumonitis after COVID‐19 vaccination
por: Shinada, Kanako, et al.
Publicado: (2021)

Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next‐generation sequencing technique
por: Manabe, Saki, et al.
Publicado: (2020)

Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures
por: Wei, Feifei, et al.
Publicado: (2023)

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
por: Ikeda, Satoshi, et al.
Publicado: (2018)

Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations
por: Murakami, Shuji, et al.
Publicado: (2022)

Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples
por: Nemoto, Daiji, et al.
Publicado: (2020)

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022)

Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer
por: Nishii, Teppei, et al.
Publicado: (2014)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Fibrotic Hypersensitivity Pneumonitis Diagnosed by a Re-evaluation with Bronchoalveolar Lavage at Disease Deterioration
por: Moda, Mitsuhiro, et al.
Publicado: (2022)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review
por: Maeda, Chihiro, et al.
Publicado: (2023)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
por: Huang, Aiben, et al.
Publicado: (2021)

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis
por: Zhou, Chengzhi, et al.
Publicado: (2022)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
por: Shigeta, Naoko, et al.
Publicado: (2023)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
por: Serzan, Michael T, et al.
Publicado: (2020)

Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis
por: Davis Puente, Andrea, et al.
Publicado: (2023)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
por: Gong, Li, et al.
Publicado: (2023)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

An unusual but unmissable link between summer-type hypersensitivity pneumonitis and asthma in an old house
por: Yasokawa, Naoya, et al.
Publicado: (2020)

High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
por: Koyama, N., et al.
Publicado: (2018)

Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy
por: Saito, Satoshi, et al.
Publicado: (2021)

Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
por: Chuzi, Sarah, et al.
Publicado: (2017)

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation
por: Zhu, Shicong, et al.
Publicado: (2020)

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies
por: Chen, Xuguang, et al.
Publicado: (2021)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
por: Ando, Hiroyuki, et al.
Publicado: (2021)

Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
por: Miao, Kang, et al.
Publicado: (2021)

The Many Faces of Immune Checkpoint Inhibitor-Associated Pneumonitis: 4 Case Reports
por: Mojsak, Damian, et al.
Publicado: (2022)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
por: Wang, Wenxian, et al.
Publicado: (2022)

A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry
por: Faucheux, Andrew, et al.
Publicado: (2023)

Early onset recall pneumonitis during targeted therapy with sunitinib
por: Yuasa, Takeshi, et al.
Publicado: (2013)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
por: Tonk, Erwin H.J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sg1r03vh5jcdagb4ueimt2sb97